Table 3.
Date | Process or Event |
---|---|
January-May 2014 | Methodology and process determined by core group from the Dana-Farber Cancer Institute and UICC. |
May 31, 2014 | UICC held planning meeting with core group plus new contributors at the Annual Meeting of the American Society of Clinical Oncology in Chicago, IL. |
June-August 2014 | A total of 22 adult cancers (including adult and pediatric cancers) as well as seven pediatric-specific cancers were included in the 2014 review process. Authors and reviewers were identified for solicitation of disease-based briefings. |
September-October 2014 | Invited authors from all over the world prepared and submitted disease-based briefings (including regimens) for the adult and pediatric cancers. |
October-November 2014 | Peer reviewers from all over the world reviewed briefings, including the treatment regimens. |
November 2014 | Dana-Farber Cancer Institute and UICC group compiled final drafts of briefings and prepared supplementary documents (eg, regulatory information, costing and price information, patent status, G-CSF briefing). |
November 17-19, 2014 | Cancer Medicines Working Group meeting held in Geneva, Switzerland, with more than a dozen participants from around the world. Each cancer briefing was reviewed in detail, and all input was recorded in real time. Long-term solutions were also discussed. |
November-December 2014 | Disease briefings were revised according to working group input and finalized for submission; 52 cancer medicines were recommended in the review, and 22 of those medicines were not yet included in the current WHO Model List. |
December 15, 2014 | Application submitted to the WHO Medicines Secretariat. |
January 7, 2015 | Application posted online on WHO Web site for public comment. |
April 20-24, 2015 | WHO to host 20th Expert Committee meeting for the selection of medicines to the 2015 Model List of Essential Medicines. |
Abbreviations: G-CSF, granulocyte colony-stimulating factor; UICC, Union for International Cancer Control.